Starjemza, formerly known as BAT2206, is a human interleukin (IL)-12 and IL-23 antagonist indicated for the treatment of: Results showed comparable efficacy between Starjemza and Stelara based on the ...

The FDA has approved Starjemza (ustekinumab-hmny) as a biosimilar to Stelara for treating various rheumatic and gastrointestinal conditions. 1 It is the eighth ustekinumab biosimilar approved in the ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases.

Extensive analytical characterization between Starjemza and US and EU Stelara was conducted on structural, physicochemical, and biological properties to support bio-similarity of Starjemza. A ...

GUANGZHOU, China and LONDON, UK I May 27, 2025 I Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma ...

a biosimilar referencing Stelara ® (ustekinumab) Injection. STARJEMZA ® is Bio-Thera's third FDA approved product. Bio-Thera and Hikma entered into a license and commercialization agreement for ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative ...

Extensive analytical characterization between STARJEMZA® and US and EU Stelara® was conducted on structural, physicochemical, and biological properties to support bio-similarity of STARJEMZA®.

a biosimilar referencing Stelara ® (ustekinumab) Injection. STARJEMZA ® is Bio-Thera's third FDA approved product. (PRNewsfoto/Hikma Pharmaceuticals USA Inc.) "This approval and our partnership ...

The FDA has approved Starjemza (ustekinumab-hmny) as a biosimilar to Stelara (ustekinumab) for the treatment of several rheumatic and gastrointestinal conditions. 1 Starjemza, developed as part of a ...

The U.S. Food and Drug Administration (FDA) has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing Stelara (ustekinumab) Injection. Bio-Thera and Hikma entered into a license ...